Abstract
Purpose
Germline mutations in the four genes that encode the succinate dehydrogenase complex (SDHx) are a risk factor for developing pheochromocytomas and/or paragangliomas. The precise genotype–phenotype correlations are still uncertain and the most common SDHx genetic defects in the Portuguese population are poorly described. The objectives of our study were to characterize the genetic alterations, clinical features, and treatment outcomes of a cohort of SDHx-related pheochromocytomas and/or paragangliomas patients.
Methods
Single center, retrospective analysis based on the presence of a SDHx mutation in cases diagnosed from 1986 until October 2016.
Results
Thirty cases were included. The mean age at diagnosis was 36.8 years (±15.4 years) and 53.3% were females. Remission was observed in 33.3% and stable disease (including partial responses) in 53.0%. SDHC and SDHD patients were prone to develop single and multiple head and neck paragangliomas, respectively. SDHB patients carried an increased risk of malignancy. Deletions in SDHB exon-1 and in SDHD exon-4 were the most common genetic findings. SDHB patients and head and neck paragangliomas had the worse prognosis, the former related to malignancy, and the latter to cranial nerve deficits, unresectable disease, and multimodality interventions. Peptide receptor radionuclide therapy and radioactive iodine MIBG therapy proved to be ineffective. Radiotherapy represented a good alternative in unresectable head and neck paragangliomas and in bone metastases.
Conclusion
This single center study is the most complete Portuguese cohort in the literature and helps to understand the behavior of tumors based on their genotype and anatomical location.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study is available upon request from the corresponding author. Due to privacy restrictions it is not publicly available.
References
P.F. Plouin, L. Amar, O.M. Dekkers, M. Fassnacht, A.P. Gimenez-Roqueplo, J.W. Lenders, et al., Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur. J. Endocrinol. 174, G1–G10 (2016)
V. Kantorovich, K.S. King, K. Pacak, SDH-related pheochromocytoma and paraganglioma. Best. Pr. Res Clin. Endocrinol. Metab. 24, 415–424 (2010)
H.J. Timmers, A.P. Gimenez-Roqueplo, M. Mannelli, K. Pacak, Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 16, 391–400 (2009)
Y. Huang, L.A. Wang, Q. Xie, J. Pang, L. Wang, Y. Yi et al., Germline SDHB and SDHD mutations in pheochromocytoma and paraganglioma patients. Endocr. Connect. 7, 1217–1225 (2018)
S.M.J. Fliedner, G. Brabant, H. Lehnert, Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype. Cell Tissue Res. 372, 347–365 (2018)
D.E. Benn, A.P. Gimenez-Roqueplo, J.R. Reilly, J. Bertherat, J. Burgess, K. Byth et al., Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab. 91, 827–836 (2006)
D.E. Benn, B.G. Robinson, R.J. Clifton-Bligh, 15 YEARS OF PARAGANGLIOMA: clinical manifestations of paraganglioma syndromes types 1-5. Endocr. Relat. Cancer 22, T91–T103 (2015)
E. Sbardella, T. Cranston, A.M. Isidori, B. Shine, A. Pal, B. Jafar-Mohammadi et al., Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. Endocrine 59, 175–182 (2018)
L.J. Castro-Vega, A. Buffet, A.A. De Cubas, A. Cascón, M. Menara, E. Khalifa et al., Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum. Mol. Genet. 23, 2440–2446 (2014)
H.P. Neumann, M. Sullivan, A. Winter, A. Malinoc, M.M. Hoffmann, C.C. Boedeker et al., Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J. Clin. Endocrinol. Metab. 96, E1279–E1282 (2011)
N. Burnichon, A. Cascon, F. Schiavi, N.P. Morales, I. Comino-Méndez, N. Abermil et al., MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin. Cancer Res. 18, 2828–2837 (2012)
B.E. Baysal, J.E. Willett-Brozick, E.C. Lawrence, C.M. Drovdlic, S.A. Savul, D.R. McLeod et al., Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med Genet. 39, 178–183 (2002)
P.T. Kavinga Gunawardane, A. Grossman, The clinical genetics of phaeochromocytoma and paraganglioma. Arch. Endocrinol. Metab. 61, 490–500 (2017)
E. Baudin, M.A. Habra, F. Deschamps, G. Cote, F. Dumont, M. Cabanillas et al., Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur. J. Endocrinol. 171, R111–R122 (2014)
J.W. Lenders, Q.Y. Duh, G. Eisenhofer, A.P. Gimenez-Roqueplo, S.K. Grebe, M.H. Murad et al., Endocrine Society: Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014)
R.G. Martins, J.B. Nunes, V. Maximo, P. Soares, J. Peixoto, T. Catarino et al., A founder SDHB mutation in Portuguese paraganglioma patients. Endocr. Relat. Cancer 20, L23–L26 (2013)
B.E. Baysal, E.R. Maher, 15 YEARS OF PARAGANGLIOMA: genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. Endocr. Relat. Cancer 22, T71–T82 (2015)
F. Castinetti, A. Kroiss, R. Kumar, K. Pacak, D. Taleb, 15 YEARS OF PARAGANGLIOMA: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 22, T135–T145 (2015)
LOVD3, Global Variome shared LOVD. https://databases.lovd.nl/shared/transcripts (2018). Accessed 22 Oct 2018
E.F. Hensen, M.D. Siemers, J.C. Jansen, E.P. Corssmit, J.A. Romijn, C.M. Tops et al., Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin. Endocrinol. 75, 650–655 (2011)
NCBI, ClinVar 2018. https://www.ncbi.nlm.nih.gov/clinvar/variation/12791/ (2018). Accessed Dec 2018
R.J. Santos, P. Montalvão, M. Magalhães, M.J. Bugalho, Paragangliomas, caracterização clínica e funcional de 40 casos. Revista Portuguese de Endocrinologia, Diabetes e. Metabolismo 6, 7–14 (2011)
H.P. Neumann, Z. Erlic, C.C. Boedeker, L.A. Rybicki, M. Robledo, M. Hermsen et al., Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 69, 3650–3656 (2009)
ClinVar Miner 2018, List of variants in gene SDHD reported as uncertain significance for Pheochromocytoma. https://clinvarminer.genetics.utah.edu/variants-by-gene/SDHD/condition/Pheochromocytoma/uncertain%20significance (2018). Accessed 22 Oct 2018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by our center’s ethic committee and complies with the Declaration of Helsinki.
Informed consent
Confidentiality was kept throughout the study and all patients or representatives signed an informed consent authorizing genetic testing and analysis of the results after full explanation of the purpose and nature of all procedures used.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Donato, S., Simões, H., Pinto, A.T. et al. SDHx-related pheochromocytoma/paraganglioma – genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. Endocrine 65, 408–415 (2019). https://doi.org/10.1007/s12020-019-01953-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01953-6